MedPath

Amubarvimab

Generic Name
Amubarvimab
Indication

本品联合罗米司韦单抗注射液用于治疗轻型和普通型且伴有进展为重型(包括住院或死亡)高风险因素的成人和青少年(12—17岁,体重≥40kg)新型冠状病毒感染(COVID-19)患者。其中,青少年(12—17岁,体重≥40kg)适应症人群为附条件批准。

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

Phase 1
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2020-07-21
Last Posted Date
2023-03-03
Lead Sponsor
Brii Biosciences Limited
Target Recruit Count
16
Registration Number
NCT04479631
Locations
🇨🇳

Investigative Site, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath